Form 4: Century Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $2.9955 under a pre-arranged trading plan.

Summary

• On May 20, 2024, Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $2.9955 per share.
• The transactions were carried out under a Rule 10b5-1 trading plan adopted on January 9, 2024.
• Following the transaction, Russotti directly owns 287,319 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 trading plan suggests that the executive planned the sale in advance to avoid any concerns about insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates